Rivia, the Zurich-based data engine for clinical trial intelligence, today announced a $15 million Series A led by Earlybird, with participation from Defiant and existing investors Speedinvest, Amino Collective, and Nina Capital.
Over the past three years, the company built what it calls the first reusable intelligence layer for clinical trials.
Its data engine integrates thousands of heterogeneou...
The article presents Rivia as a crucial corrective to a fundamentally broken clinical trial infrastructure, a situation ripe for exploitation by a new, agentic approach. The “scarcity narrative” – tightened regulation, plummeting pharma returns – is expertly deployed to justify the company’s existence. The core problem isn't simply data volume; it’s the *architecture* of the existing systems – designed for passive data capture, not active analysis across a massively complex, multi-vendor ecosyst...